日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study)

EGFR 突变转移性非小细胞肺癌对雷莫芦单抗的突变特异性反应：来自循环游离 DNA 分析的启示（RELAY 3 期随机研究的液体活检日本附录）

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2026.100963
Nishio, Kazuto; Sakai, Kazuko; Nishio, Makoto; Seto, Takashi; Visseren-Grul, Carla; Carlsen, Michelle; Enatsu, Sotaro; Matsui, Tomoko; Nakagawa, Kazuhiko
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2026
文献求助 收藏

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

RELAY+：雷莫芦单抗联合吉非替尼治疗未经治疗的EGFR突变转移性非小细胞肺癌患者的最终总生存期

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2025.100912
Nishio, Makoto; Seto, Takashi; Reck, Martin; Garon, Edward B; Nishio, Kazuto; Kasahara, Kazuo; Nishino, Kazumi; Satouchi, Miyako; Yoh, Kiyotaka; Hayashi, Hidetoshi; Sakai, Kazuko; Enatsu, Sotaro; Matsui, Tomoko; Varughese, Sunoj Chacko; Carlsen, Michelle; Visseren-Grul, Carla; Nakagawa, Kazuhiko
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2025
文献求助 收藏

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

在未经治疗的EGFR突变转移性非小细胞肺癌患者中，雷莫芦单抗联合厄洛替尼与安慰剂联合厄洛替尼的最终生存结果：RELAY日本亚组

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2025.100819
Nishio, Makoto; Seto, Takashi; Reck, Martin; Garon, Edward B; Nishio, Kazuto; Kasahara, Kazuo; Nishino, Kazumi; Satouchi, Miyako; Yoh, Kiyotaka; Hayashi, Hidetoshi; Sakai, Kazuko; Enatsu, Sotaro; Frimodt-Møller, Bente; Matsui, Tomoko; Varughese, Sunoj Chacko; Carlsen, Michelle; Visseren-Grul, Carla; Nakagawa, Kazuhiko
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2025
文献求助 收藏

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

RELAY 研究：厄洛替尼联合雷莫芦单抗治疗未经治疗的 EGFR 突变转移性非小细胞肺癌：按 EGFR 19 号外显子缺失变异体分析的疗效

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2023.100624
Nishino, Kazumi; Shih, Jin-Yuan; Nakagawa, Kazuhiko; Reck, Martin; Garon, Edward B; Carlsen, Michelle; Matsui, Tomoko; Visseren-Grul, Carla; Nadal, Ernest
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2024
文献求助 收藏

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.

集落刺激因子-1受体抑制剂在晚期难治性乳腺癌或前列腺癌患者中的免疫调节活性：一项I期研究

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-20-0855
Autio Karen A, Klebanoff Christopher A, Schaer David, Kauh John Sae Wook, Slovin Susan F, Adamow Matthew, Blinder Victoria S, Brahmachary Manisha, Carlsen Michelle, Comen Elizabeth, Danila Daniel C, Doman Thompson N, Durack Jeremy C, Fox Josef J, Gluskin Jill S, Hoffman David M, Kang Suhyun, Kang Praneet, Landa Jonathan, McAndrew Philomena F, Modi Shanu, Morris Michael J, Novosiadly Ruslan, Rathkopf Dana E, Sanford Rachel, Chapman Sonya C, Tate Courtney M, Yu Danni, Wong Phillip, McArthur Heather L
免疫/内分泌
乳腺癌
前列腺癌
发表日期：2020
文献求助 收藏